Schizophrenia Market is projected to reach USD 7.2 Billion in 2018 and expected to register a 2.5% CAGR during the forecast period. Schizophrenia is a long-term mental disorder involving a breakdown in the relation between thought, emotion, and behavior. Although the course of schizophrenia varies among individuals, it is typically persistent and can be both severe and disabling.
The primary factors driving the growth of the global schizophrenia market are rising cases of schizophrenia, a growing number of geriatric individuals, and increasing research and development in schizophrenia treatment. According to the National Institute of Mental Health (NIMH), schizophrenia is one of the top 15 leading causes of disability worldwide. According to the Schizophrenia and Related Disorders Alliance of America, schizophrenia can be found in approximately 1.1% of the world’s population, regardless of racial, ethnic, or economic background. However, stringent regulations around new product approvals and rising generic launches are hampering the growth of the global market.
Segmentation
The Global Schizophrenia Market has been segmented into type, treatment, and route of administration.
By type, the global market has been segmented into paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and undifferentiated schizophrenia.
Based on treatment, the global market has been divided into second-generation antipsychotics and third-generation antipsychotics. The second-generation antipsychotics segment is further sub-segmented into Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone), and others.
Based on route of administration, the global market has been bifurcated into oral and injectables.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The schizophrenia market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European schizophrenia market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The schizophrenia market in Asia-Pacific has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific. The schizophrenia market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Johnson & Johnson (US), Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals (US), AstraZeneca (UK), Eli Lilly (US), Alkermes (Ireland), Sumitomo Dainippon Pharma (Japan)
Pfizer (US), Vanda Pharmaceuticals (US), and Allergan/Geodon Ritcher (Ireland) are some of the key players operating in the global schizophrenia market.
Global Schizophrenia Market, by Type
- Paranoid Schizophrenia
- Hebephrenic Schizophrenia
- Catatonic Schizophrenia
- Undifferentiated Schizophrenia
Global Schizophrenia Market, by Treatment
- Second-Generation Antipsychotics
- Risperdal (Risperidone)
- Invega (Paliperidone)
- Zyprexa (Olanzapine)
- Geodon (Ziprasidone)
- Seroquel (Quetiapine)
- Latuda (Lurasidone)
- Others
- Third-Generation Antipsychotics
Global Schizophrenia Market, by Route of Administration
Request Customization
Get a Sample
Get a Sample
Request Customization